Novartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 17.4%, free cash flow fell 15.5% and total debt rose 52.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three, operating cash flow growth for three.
Follow NVS
Novartis AG (NVS) EV/Sales
As of 16 October 2026, Novartis AG (NVS) trades at a EV/Sales of 5.8×. Over the past ten years it has ranged from −1.6× (January 2018) to 6.2× (September 2026); the current reading is higher than 97% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.1× | 24.23% |
| FY2024 | 4.1× | (12.84%) |
| FY2023 | 4.7× | (1.67%) |
| FY2022 | 4.8× | 28.64% |
| FY2021 | 3.7× | (22.36%) |
| FY2020 | 4.8× | 0.33% |
| FY2019 | 4.8× | 13.39% |
| FY2018 | 4.2× | — |
| FY2017 | −1.4× | — |
| FY2016 | −1.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.0× | 2.30% |
| Mar 2026 | 5.8× | 14.16% |
| Dec 2025 | 5.1× | 7.62% |
| Sep 2025 | 4.7× | 0.85% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PFE Pfizer Inc. compare | 3.5× |
| NVO Novo Nordisk A/S compare | 3.6× |
| AZN AstraZeneca PLC compare | 4.6× |
| NVS Novartis AG | 5.8× |
| MRK Merck & Co., Inc. compare | 6.1× |
| JNJ Johnson & Johnson compare | 6.4× |
| GILD Gilead Sciences, Inc. compare | 7.1× |
| AMGN Amgen Inc. compare | 7.3× |
| ABBV AbbVie Inc. compare | 8.8× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)